Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

4118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-31

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

While the efficacy of aspirin for the secondary prevention of cardiovascular disease is evident, the effect of aspirin for primary prevention is unclear. The use of aspirin reduces cardiovascular mortality and myocardial infarction but increases side effects such as bleeding. Therefore, the use of aspirin for primary prevention in people without cardiovascular disease should be determined by individual risk and clinical benefit. The European guidelines have been changed to not recommend aspirin use in people without cardiovascular disease, but there are still people taking aspirin for primary prevention. The purpose of this study is to investigate the effect of aspirin withdrawal on cardiovascular events in patients without cardiovascular disease.

This is a single center, prospective, randomized clinical study evaluating the safety and efficacy of withdrawal of aspirin among patients with moderate or high cardiovascular risk.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aspirin Effectiveness Study

NCT01113060

Coronary Artery Disease

UNKNOWN

Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization

NCT05347069

Stable Angina Pectoris Coronary Artery Disease Ischemic Heart Disease

RECRUITING PHASE4

Improving Aspirin Use Among Adults at Risk for Cardiovascular Disease (CVD)

NCT00981032

Cardiovascular Disease

COMPLETED NA

Aspirin Response in High Risk Patients With Coronary Artery Disease

NCT01383304

Coronary Artery Disease Myocardial Infarction Diabetes Mellitus +1 more

UNKNOWN

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

NCT02596126

Myocardial Infarction Cardiovascular Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients taking aspirin will be randomly assigned to a group that maintains taking aspirin and a group that discontinues to take aspirin by 1:1 manner. The follow-up duration is five years and clinical outcomes will be investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants With Moderate and High Cardiovascular Risk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Aspirin maintenance group versus aspirin interruption group

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspirin maintenance group

People who are taking aspirin continue to take aspirin.

Group Type NO_INTERVENTION

No interventions assigned to this group

Aspirin withdrawal group

People who are taking aspirin stop to taking aspirin.

Group Type EXPERIMENTAL

Withdrawal of aspirin

Intervention Type OTHER

People who are taking aspirin stop to taking aspirin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Withdrawal of aspirin

People who are taking aspirin stop to taking aspirin.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 19-80 years old
* Subjects who are taking for more than 12 months
* Subjects with moderate or high cardiovascular risk based on cardiovascular risk classification of 2015 Korea Society of Lipidology And Atherosclerosis guideline or 2004 American Heart Association guideline: 1) moderate risk: people with ≥2 major risk factors, 2) high risk: people with carotid atherosclerosis, abdominal aortic aneurysm, or diabetes, who is taking statin
* Subjects who voluntarily participate in the study and sign informed consent form

Exclusion Criteria

* Subjects with a history of major cardiovascular disease confirmed by medical history and medical history; myocardial infarction, angina pectoris, coronary angioplasty, coronary artery bypass surgery, peripheral vascular disease, ischemic stroke, transient ischemic attack
* Subjects has any contraindication to use of aspirin or hypersensitivity to aspirin
* Subjects with atrial fibrillation
* Subjects who are taking anti-platelet agents other than aspirin or anticoagulants
* Subjects who have been diagnosed with cancer within the last 5 years
* Pregnant women or those who have pregnancy plan after enrolling in this study

Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes